Concomitant EGFR and KRAS mutations in ALK-rearranged lung cancer

We would add here new information on the subset of NSCLC with concomitant ALK rearrangement and mutations not only in EGFR, as described by Won JK et al in the February issue of Annals of Oncology, but also in KRAS. KRAS mutations in ALK rearranged NSCLC do seem to represent a novel mechanism of primary resistance to crizotinib that merits further confirmation on larger series of cases.